Ultime notizie per SILO Pharma (NASDAQ:SILO) Azioni

SILO Pharma

SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.

SILO Pharma Inc

Silo Wellness Inc

Qualigen Therapeutics, Inc. - Common Stock

QLGN

Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times

On CNBC's &#8220;<a href="https://www.cnbc.com/video/2024/11/04/final-trades-starbucks-freeport-mcmoran-constellation-energy-and-the-xlu.html">Halftime Report Final Trades</a>,&#8221; Joshua Brown of Ritholtz Wealth Management said he is keeping an eye on Starbucks Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>). The stock is expected to make another run at $100, he added.
On Oct. 30, Starbucks reported weaker-than-expected fourth-quarter results. The company posted quarterly earnings of 80 cents per share which missed the analyst consensus estimate of $1.03 per share. The company reported quarterly sales of $9.074 billion which missed the analyst consensus <a href="https://www.benzinga.com/news/earnings/24/10/41634203/starbucks-likely-to-report-lower-quarterly-earnings-these-most-accurate-analysts-revise-forecasts-a">estimate of $9.375 billion.</a>
Don't forget to check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
Shannon Saccocia of NB Private Wealth named The Utilities Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>) as <a href="https://www.benzinga.com/quote/XLU">her final trade.</a>
Sarat Sethi of DCLA named Freeport-McMoRan Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FCX#NYSE">FCX</a>) as his final trade.
On Oct. 22, Freeport-McMoRan reported third-quarter FY24 results. Revenue stood at $6.79 billion, beating the consensus of $6.47 billion. Copper sales totaled 1.0 billion pounds, down 7% Y/Y and 2% above the July 2024 estimate, due to the timing of shipments and lower ore grades and operating rates in North America.
Joseph M. Terranova of Virtus Investment Partners picked Constellation Energy Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CEG#NASDAQ">CEG</a>), which pulled back on Monday.
On Nov. 4, Constellation Energy reported third-quarter results and revised its FY24 adjusted EPS guidance, which is below estimates.
Price Action:
<ul>
<li>The Utilities Select Sector SPDR Fund fell 1.2% during Monday's session.</li>
<li>Starbucks shares fell 1.9% to settle at $97.03 during Monday's session.</li>
<li>Freeport-McMoRan shares gained 1.5% to close at $46.27 on Monday.</li>
<li>Constellation Energy shares fell 12.5% to settle at $225.95 on Monday.</li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/news/24/11/41713185/top-4-tech-and-telecom-stocks-that-may-collapse-this-month">Top 4 Tech And Telecom Stocks That May Collapse This Month</a></li>
</ul>
Image: Shutterstock

Long Ideas

News

Markets

Media

Trading Ideas

SBUX

Starbucks, Freeport-McMoRan, Constellation Energy And More On CNBC's 'Final Trades'

Barclays analyst Michael Leithead maintains Chemours (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CC#NYSE">CC</a>) with a Equal-Weight and raises the price target from $21 to $23.

Price Target

Analyst Ratings

Barclays Maintains Equal-Weight on Chemours, Raises Price Target to $23

<a href="https://www.benzinga.com/topic/2024-election">Election Day has arrived</a>, and we could all probably use a deep breath. Take a moment if you need it.
Now, onto the cannabis front where voters in Nebraska, North Dakota, South Dakota and Florida <a href="https://www.benzinga.com/markets/cannabis/24/10/41387752/winding-road-to-cannabis-legalization-ahead-for-4-states-set-to-vote-in-2024-what-do-the-polls-s">will decide on ballot initiatives</a> to legalize marijuana for recreational or medical use. If approved, these states will join the 38 others that have embraced some form of cannabis legalization and join the rapidly changing landscape of <a href="https://www.benzinga.com/topic/cannabis-reform">marijuana policy</a> in the U.S.
Here's what&#8217;s changed in the landscape…some might even say drastically.
<h3 class="wp-block-heading">One Of Our Favorites: Adult Weed Consumption Rises As Teen Use Falls</h3>
Concerns over a spike in youth cannabis consumption following early legalization efforts, beginning with Colorado and Washington in 2012, have proven unfounded. Contrary to fears, marijuana use among teens has declined, or maybe never really took off.
From 2011 to 2021, the <a href="https://www.benzinga.com/topic/cannabis-reform">percentage of adolescents reporting marijuana use</a> dropped from 23% to under 16%.
"The ‘sky's going to fall' scenario was that all of the kids were just going to have access to all of the cannabis and it was going to be a terrible, terrible thing," said Ryan Vandrey, professor of psychiatry and behavioral sciences at Johns Hopkins Medicine who studies cannabis.
"It just goes to show that teenagers will do exactly the opposite of what you think they're going to do at all times," Vandrey <a href="https://www.nytimes.com/2024/11/04/well/weed-cannabis-america.html">told</a> The New York Times, confirming what every parent who has or is raising a teenager already knows.
Adult cannabis consumption, meanwhile, <a href="https://www.benzinga.com/markets/cannabis/24/08/40652731/cannabis-and-hallucinogen-consumption-hit-all-time-highs-in-2023-while-tobacco-and-alcohol-decli">has reached historic highs</a>, with 42% of individuals aged 19-30 and 29% of those aged 35-50 reporting use in the past year.
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/10/41609840/sharp-drop-in-teen-marijuana-use-legalization-and-demographics-examined">Sharp Drop In Teen Marijuana Use: Legalization And Demographics Examined</a>
<h3 class="wp-block-heading">Cannabis Use Surpasses Alcohol</h3>
Yeah, you read that right. Recent studies have show that more Americans are now consuming <a href="https://www.benzinga.com/markets/cannabis/24/05/38976556/daily-cannabis-consumption-outpaces-daily-alcohol-use-in-the-us-for-the-first-time-new-study-sho">weed daily rather than alcohol</a>. Nearly 18 million people report daily or near-daily marijuana use, outpacing the 15 million who drink with similar frequency. 
<h3 class="wp-block-heading">Seniors Jump On The Weed Wagon Because…Why Not?</h3>
The country&#8217;s 73 million baby boomers are among the&nbsp;<a href="https://www.benzinga.com/markets/cannabis/23/08/33583433/baby-boomers-turning-to-weed-en-masse-say-it-improves-memory-and-mood-doctors-agree-cnn-series-e" target="_blank" rel="noreferrer noopener">fastest-growing demographic</a><a href="https://www.benzinga.com/markets/cannabis/24/01/36458087/senior-cannabis-consumers-balancing-act-relief-for-numerous-conditions-comes-with-warnings-but-w" target="_blank" rel="noreferrer noopener">&nbsp;</a>of&nbsp;cannabis users in the U.S. and around the world. In the past 8 years, senior cannabis consumption has tripled. Seniors also happen to&nbsp;possess&nbsp;half of the nation's&nbsp;$140 trillion&nbsp;in wealth, so they&#8217;re helping the economy even after they&#8217;ve retired.
<h3 class="wp-block-heading">Closing That Gender Gap </h3>
Cannabis use has long been more prevalent among men than women, but that disparity is shrinking. In 2023, young women (ages 19-30) <a href="https://www.benzinga.com/markets/cannabis/24/08/40652731/cannabis-and-hallucinogen-consumption-hit-all-time-highs-in-2023-while-tobacco-and-alcohol-decli">reported higher rates of cannabis use</a> than their male counterparts. Teenage girls also now report higher marijuana use than boys, marking a shift in gender patterns of cannabis consumption.
Now Read: 
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/11/41726320/hemp-donations-fuel-desantis-and-florida-gops-charge-against-weed-legalization-new-findings">Hemp Donations Fuel DeSantis And Florida GOP&#8217;s Charge Against Weed Legalization, New Findings</a></li>
</ul>
Photo: Shutterstock

Cannabis

Government

Politics

Legal

Election Day 2024: Will Florida, Nebraska, North And South Dakota Join The Marijuana Revolution?

Barclays analyst Tom O'Malley maintains Astera Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALAB#NASDAQ">ALAB</a>) with a Overweight and raises the price target from $70 to $87.

ALAB

Barclays Maintains Overweight on Astera Labs, Raises Price Target to $87

Barclays analyst Julian Mitchell maintains APi Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APG#NYSE">APG</a>) with a Overweight and raises the price target from $43 to $44.

Barclays Maintains Overweight on APi Gr, Raises Price Target to $44

KITT

Nauticus Robotics Secures Agreement To Convert $33M Debt Into Equity Via Preferred Stock Exchange, Aiming To Deleverage Balance Sheet And Address Nasdaq Compliance

On CNBC's &#8220;Mad Money Lightning Round,&#8221; Jim Cramer said Ceva (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CEVA#NYSE">CEVA</a>) is &#8220;way too high, and I think you <a href="https://www.benzinga.com/quote/CEVA">should take something off the table.&#8221;</a>
Ceva will announce results for the third quarter on Nov. 7, 2024, before the opening bell.
&#8220;I love space stuff, and that's why I keep recommending Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>),&#8221; Cramer said when asked about Intuitive Machines, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUNR#NASDAQ">LUNR</a>). If there's going to be something in space, it is going to be done by Elon Musk."
Intuitive Machines will release its financial results for the third quarter on Thursday, Nov. 14, before the market opens.
When asked about Ford Motor Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>), &#8220;I want so badly for the company to do well, but I can't recommend the stock.&#8221;
The company is reportedly set to pause production of its F-150 Lightning from mid-November until the year&#8217;s end, citing weaker-than-anticipated demand for the electric pickup, Automotive News reported.
&#8220;They are in the oil service business, and oil is not a growth commodity. So, I'm going to say you can't own the stock here, as much as I really like them,&#8221; the &#8220;Mad Money&#8221; host said when asked about SLB (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLB#NYSE">SLB</a>).
The company, last week, disclosed that its OneSubsea joint venture won a contract from BP p.l.c. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BP#NYSE">BP</a>) for a subsea boosting system as part of the greenfield development of the Kaskida project in the deepwater U.S.
Cramer recommended taking something off the table, when asked about Vistra Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VST#NYSE">VST</a>).
Vistra will replace The AES Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AES#NYSE">AES</a>) in the Dow Jones Utility Average, effective prior to the open of trading on Friday, Nov. 8.
Price Action:
<ul>
<li>CEVA shares fell 0.2% to settle at $23.64 on Monday.</li>
<li>Intuitive Machines shares fell 6.5% to close at $7.58 on Monday.</li>
<li>Ford shares gained 1.4% to settle at $10.36 during the session.</li>
<li>SLB gained 1.4% to settle at $40.32 on Monday.</li>
<li>Vistra shares fell 3.2% to close at $115.74.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/24/11/41713185/top-4-tech-and-telecom-stocks-that-may-collapse-this-month">Top 4 Tech And Telecom Stocks That May Collapse This Month</a></li>
</ul>

CEVA

LUNR

TSLA

Jim Cramer Says He Can't Recommend This Major Automaker, Ceva Is 'Way Too High'

WIIM

DuPont shares are trading higher after the company reported better-than-expected Q3 EPS and raised its FY24 adjusted EPS guidance.

APLS

Apellis Pharmaceuticals shares are trading lower after the company reported worse-than-expected Q3 financial results.

Barclays analyst Matt Miksic maintains Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) with a Overweight and raises the price target from $143 to $149.

Barclays Maintains Overweight on Abbott Laboratories, Raises Price Target to $149

Pfizer's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) short percent of float has risen 5.04% since its last report. The company recently reported that it has 70.94 million shares sold short, which is 1.25% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.22 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Pfizer Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730814324_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Pfizer has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Pfizer's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Pfizer's peer group average for short interest as a percentage of float is 4.87%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Peering Into Pfizer's Recent Short Interest

KKR's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KKR#NYSE">KKR</a>) short percent of float has fallen 13.57% since its last report. The company recently reported that it has 11.63 million shares sold short, which is 1.72% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.97 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>KKR Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730814319_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for KKR has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing KKR's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, KKR's peer group average for short interest as a percentage of float is 3.67%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Looking Into KKR's Recent Short Interest

PDD Holdings's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PDD#NYSE">PDD</a>) short percent of float has fallen 7.83% since its last report. The company recently reported that it has 32.98 million shares sold short, which is 4.0% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.69 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>PDD Holdings Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730814314_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for PDD Holdings has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing PDD Holdings's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, PDD Holdings's peer group average for short interest as a percentage of float is 9.86%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Citigourp Global Markets 2% Protected Notes Linked To The Djia

Looking Into PDD Holdings's Recent Short Interest

Barclays analyst Steven Valiquette maintains Owens &amp; Minor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OMI#NYSE">OMI</a>) with a Equal-Weight and lowers the price target from $18 to $14.

Barclays Maintains Equal-Weight on Owens & Minor, Lowers Price Target to $14

AHCO

AdaptHealth Corp shares are trading lower after the company reported worse-than-expected Q3 sales and revised its FY24 net revenue guidance

Cleveland-Cliffs shares are trading lower following worse-than-expected Q3 financial results.

LSCC

Lattice Semiconductor shares are trading lower following soft Q4 guidance.

Mission Produce shares are trading higher after the company raised its Q4 guidance above estimates.

Barclays analyst Gena Wang maintains BioCryst Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCRX#NASDAQ">BCRX</a>) with a Equal-Weight and raises the price target from $7 to $8.

BCRX

Barclays Maintains Equal-Weight on BioCryst Pharma, Raises Price Target to $8

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Silo Pharma&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/silo-stock-quote/">SILO</a>) stock is rocketing higher on Tuesday after the developmental stage biopharmaceutical company <a href="https://www.nasdaq.com/press-release/silo-pharma-secures-exclusive-global-license-alzheimers-therapeutic-2024-07-16">secured a new global license</a>.



This license covers the development, manufacturing, and commercialization of its Alzheimer&rsquo;s drug SPC-14. It also intends to use the Food and Drug Administration&rsquo;s (FDA) streamlined 505(b)(2) pathway for speedy clinical trials.



Silo Pharma&nbsp;CEO&nbsp;Eric Weisblum said the following about the new license deal.




&ldquo;In our view, our exclusive license for SPC-14 gives us the potential to meet a large unmet medical need. If approved, we believe SPC-14 could bring hope and relief for many families and patients. Early pre-clinical studies have shown stress reduction and cognitive improvement.&rdquo;




<h2>What This Means for SILO Stock</h2>



Development of a new Alzheimer&rsquo;s drug is a big deal. The market for Alzheimer&rsquo;s disease therapeutics is expected to be more than 30.8 billion&nbsp;by 2033. This new treatment could earn Silo Pharma a share of that market.



SILO stock is up 122.5% as of Tuesday morning. That comes with some 15 million shares traded. This is well above the company&rsquo;s daily average trading volume of about 257,000 shares. Investors will note the stock was down 29.6% year-to-date when markets closed yesterday.



Investors will want to stick around for even more of the most recent stock market stories on Tuesday!



We have all of the hottest market news traders need to know about today! That includes the biggest pre-market stock movers and more of the latest stock market coverage! You can catch up on all of that at the links below!



<h2>More Tuesday Stock Market News</h2>



<ul><li><a href="https://investorplace.com/2024/07/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-tuesday-july-16th/">Today&rsquo;s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on&nbsp;Tuesday</a></li>



<li><a href="https://investorplace.com/2024/07/wolfe-research-says-to-bet-big-on-coinbase-coin-stock-if-trump-wins-in-november/">Wolfe Research Says to Bet Big on Coinbase (COIN) Stock If Trump Wins in November</a></li>



<li><a href="https://investorplace.com/2024/07/dear-mstr-stock-fans-mark-your-calendars-for-july-27/">Dear MSTR Stock Fans, Mark Your Calendars for July 27</a></li>
</ul>On Penny Stocks and Low-Volume Stocks:&#8239;With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.



Read More:&#8239;Penny Stocks &mdash;&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank">How to Profit Without Getting Scammed</a>



On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/07/why-is-silo-pharma-silo-stock-up-123-today/">Why Is Silo Pharma (SILO) Stock Up 123% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is Silo Pharma (SILO) Stock Up 123% Today?

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Greenpro Capital&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/grnq-stock-quote/">GRNQ</a>) stock is dropping on Tuesday after the financial consulting and corporate advisory services company&rsquo;s shares underwent a large rally during the prior day of trading.



This saw shares of GRNQ stock close out normal trading hours on Monday up more than 34%. That came with heavy trading as over 10 million units moved yesterday. To put that number in perspective, the daily average trading volume for Greenpro Capital shares is around 183,000.



This rally didn&rsquo;t come without any news. The catalyst behind it was Greenpro Capital announcing a new strategic partnership. This brings together Greenpro Capital, its subsidiary Green-X and Bank Islam Trust Company.



Greenpro Capital CEO Dr. CK Lee <a href="https://www.nasdaq.com/press-release/greenpro-capital-corp-and-green-x-corp-forms-strategic-alliance-bank-islam-trust">said this about the strategic alliance</a>.




&ldquo;We are extremely excited to have&nbsp;Bank Islam Trust&nbsp;as our strategic partner to penetrate the Muslim and&nbsp;Middle East&nbsp;communities. There is a huge demand for digital asset investments from the&nbsp;Middle East, and we will structure our STO and RWA assets as alternative investment products to cater to their demand.&rdquo;




<h2>GRNQ Stock Movement Today</h2>



Considering the rally yesterday, it makes sense that GRNQ stock would give up some of those gains today. That has the stock falling 19.1% as of Tuesday morning. Traders will note that GRNQ shares were down 5.6% year-to-date when markets closed yesterday.



Today&rsquo;s stock market movement comes with some 230,000 shares of GRNQ on the move. That&rsquo;s already above Greenpro Capital&rsquo;s daily average trading volume.



Investors will want to keep reading for more of the biggest stock market stories on Tuesday!



We have all of the hottest stock market happenings to report on today! That includes the latest news for Autonomix Medical&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/amix-stock-quote/">AMIX</a>) stock, Conduit Pharmaceuticals&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/cdt-stock-quote/">CDT</a>) stock and Silo Pharma&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/silo-stock-quote/">SILO</a>) stock this morning. All of this info is ready to go at the links below!



<h2>More Stock Market News for Tuesday</h2>



<ul><li><a href="https://investorplace.com/2024/07/why-is-autonomix-medical-amix-stock-down-17-today/">Why Is Autonomix Medical (AMIX) Stock Down 17% Today?</a></li>



<li><a href="https://investorplace.com/2024/07/why-is-conduit-pharmaceuticals-cdt-stock-up-73-today/">Why Is Conduit Pharmaceuticals (CDT) Stock Up 73% Today?</a></li>



<li><a href="https://investorplace.com/2024/07/why-is-silo-pharma-silo-stock-up-123-today/">Why Is Silo Pharma (SILO) Stock Up 123% Today?</a></li>
</ul>On Penny Stocks and Low-Volume Stocks:&#8239;With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.



Read More:&#8239;Penny Stocks &mdash;&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank">How to Profit Without Getting Scammed</a>



On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/07/why-is-greenpro-capital-grnq-stock-down-19-today/">Why Is Greenpro Capital (GRNQ) Stock Down 19% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is Greenpro Capital (GRNQ) Stock Down 19% Today?

Silo Pharma files to sell 1.04M shares of common stock for holders

Silo Pharma, Aeon Biopharma, and NaaS Technology are the 3 Penny Stocks to watch on July 18, based on&nbsp;TipRanks' Penny Stock Screener tool. Pen...

3 Penny Stocks to Watch Now, 7/18/24

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Developmental-stage pharmaceutical firm Silo Pharma (NASDAQ:<a href="https://investorplace.com/stock-quotes/silo-stock-quote/">SILO</a>) &mdash; which specializes in both traditional and psychedelic therapeutics to address stress-induced psychiatric disorders &mdash; saw its shares rise dramatically on Thursday. Earlier this morning, the company announced a partnership to develop an intranasal drug to address post-traumatic stress disorder (PTSD). The news and the large addressable market appears to have catapulted SILO stock.



According to Silo&rsquo;s <a href="https://finance.yahoo.com/news/silo-pharma-resyca-bv-partner-122500980.html">press release</a>, the pharmaceutical firm entered into a partnership with Resyca BV, a medical technology provider. Resyca itself is a joint venture which manufactures a formulation-specific microchip-based spray system &mdash; a system that undergirds Silo&rsquo;s lead candidate called SPC-15. This therapeutic addresses PTSD through &ldquo;cutting-edge nose-to-brain drug dispersion,&rdquo; explained Silo CEO Eric Weisblum.



In addition, the head executive added that &ldquo;this delivery method could increase the drug&rsquo;s concentration in the brain to deliver a faster onset of therapeutic benefit and optimized safety for PTSD patients.&rdquo;



Importantly, Silo and Resyca have developed a plan to set the framework for pre-human clinical trials. Such trials are necessary before the partnership can apply for an investigational new drug (IND) from the Food and Drug Administration (FDA) to conduct human trials.



<h2>Growing Need for PTSD Solutions Fuels the Surge in SILO Stock</h2>



Naturally, the anticipation of a regulatory green light has contributed to the explosive sentiment in SILO stock. A few days ago, the underlying pharma made headlines when it announced a <a href="https://investorplace.com/2024/07/why-is-silo-pharma-silo-stock-up-123-today/">licensing deal</a> for the development of SPC-14, a therapeutic for Alzheimer&rsquo;s.



Regarding today&rsquo;s jump in SILO stock, the growing need for addressing PTSD has helped positively shift the underlying corporate narrative. Prior to the series of key developments, Silo suffered a significant drop in equity value in the past one-year period. Now, in the past five sessions, SILO has gained 260%.



According to Grand View Research, the global PTSD treatment market size <a href="https://www.grandviewresearch.com/industry-analysis/post-traumatic-stress-disorder-treatment-market-report">reached a valuation of $915.5 million in 2021</a>. Experts project a compound annual growth rate (CAGR) of 4.7% from 2022 to 2030. At the culmination point, the sector could generate revenue of $1.4 billion. However, it&rsquo;s also possible that this projection may be understated.



Presently, about one in five adults in the U.S. experience some form of <a href="https://magazine.howard.edu/stories/the-growth-of-mental-health-awareness#:~:text=and%20self%2Dcare.-,With%201%20in%205%20adults%20in%20the%20United%20States%20experiencing,wellness%2C%20especially%20on%20social%20media.">mental illness</a>. Further, as people &mdash; especially younger generations &mdash; become more vocal about mental wellness issues, demand for treatment solutions may rise. That&rsquo;s also another potential catalyst for SILO stock.



On Penny Stocks and Low-Volume Stocks:&#8239;With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.



Read More:&#8239;Penny Stocks &mdash;&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank">How to Profit Without Getting Scammed</a>



On the date of publication, Josh Enomoto did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.



On the date of publication, the responsible editor did not have (either directly or indirectly) any positions in the securities mentioned in this article.
<div>A former senior business analyst for Sony Electronics, Josh Enomoto has helped broker major contracts with Fortune Global 500 companies. Over the past several years, he has delivered unique, critical insights for the investment markets, as well as various other industries including legal, construction management, and healthcare. Tweet him at @EnomotoMedia.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/07/why-is-silo-pharma-silo-stock-up-60-today/">Why Is Silo Pharma (SILO) Stock Up 60% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is Silo Pharma (SILO) Stock Up 60% Today?

Silo Pharma stock plummets on $2.1M registered direct offering priced ATM

Silo Pharma announces partnership with global CRO for central nervous system homing peptide

Silo Pharma files for secondary stock offering

Silo Pharma ( ($SILO) ) has shared an update. Silo Pharma, Inc. has released a presentation outlining its strategic direction and product pipeline,...

Silo Pharma Outlines Strategic Direction and Innovative Pipeline

Silo Pharma (SILO) announced promising results from recent sterilization and dissolution tests of its SP-26 ketamine-loaded implant for fibromyalgi...

Comments

SILO Pharma

Notizie

Ultime notizie per SILO Pharma (NASDAQ:SILO) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO